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Glycoprotein IIb-IIIa  (GPIIb-IIIa)  is  the  fibrinogen 
receptor on activated platelets. GPIIIa  is phosphoryl- 
ated  in  resting  platelets  and  the  incorporation of 32Pi 
increases  with  platelet  activation. To address  the func- 
tional  significance of this modification, the stoichiom- 
etry of GPIIIa phosphorylation was  determined  in  rest- 
ing  and  activated  platelets by estimating the specific 
activity of metabolic [y3’P]ATP from the specific ac- 
tivity of phosphatidic acid. Approximately 0.01 mol  of 
P/mol of GPIIIa  was phosphorylated in  resting  plate- 
lets and 0.03 mol  of P/mol of GPIIIa  was phosphoryl- 
ated in thrombin-, phorbol ester-,  or  U46619-treated 
platelets. Myosin light chain (MLC) phosphorylation 
served as a positive control  for  this method (1.2 mol  of 
P/mol of MLC). Phosphorylation of purified  GPIIb-IIIa 
by human platelet  protein  kinase C (PKC) resulted  in 
levels of GPIIIa phosphorylation similar to that in 
platelets (0.05 mol  of P/mol of GPIIIa). However, while 
GPIIIa in platelets  was phosphorylated primarily on 
threonine,  purified GPIIIa treated  with PKC was phos- 
phorylated  primarily on serine. These results suggest 
that PKC may not directly phosphorylate GPIIIa in 
intact platelets. Ca2+/calmodulin-dependent kinase I1 
phosphorylated purified  GPIIIa to higher levels (0.5 
mol  of P/mol of GPIIIa)  with phosphorylation on both 
threonine  and  serine.  The limited phosphorylation of 
GPIIIa in intact  platelets  suggests that  this  event  is 
unlikely  to  affect  functions  involving large populations 
of GPIIb-IIIa, such as its conversion to  a  fibrinogen 
receptor. However, these  results may suggest the  ex- 
istence of a more readily phosphorylated subpopulation 
of GPIIb-IIIa with potentially distinct structural  or 
functional  properties. 
* This work  was supported by a  grant-in-aid from the American 
Heart Association (to L. V. P.). Additional support was provided by 
National Institutes of Health FIRST Award R29HL38405 (to L. V. 
P.), Research Fellowship in Hematology/Oncology HL07149-15 (to 
C. A. H.) and Predoctoral Training  Grant GM07040 (to S. S. S.). An 
abstract of this work was presented at the 1990 meeting of the 
American Society of Hematology, Boston, Massachusetts. The costs 
of publication of this article were defrayed in part by the payment of 
page charges. This article must therefore be hereby marked “aduer- 
tisement” in accordance with 18 U.S.C. Section 1734  solely to indicate 
this fact. 
dressed Dept. of Pharmacology, CB# 7365, 1106 FLOB, University 
ll To whom correspondence and reprint requests should be ad- 
of North Carolina, Chapel Hill, NC 27599-7365. 
11 This work was performed during the tenure of an Established 
Investigatorship from the American Heart Association. 
The glycoprotein IIb-IIIa complex (GPIIb-IIIa)’ is an abun- 
dant, multifunctional  transmembrane  protein on platelets (1). 
It is a member of the integrin family of adhesive receptors 
and is composed of a unique a-subunit  (GPIIb or a ~ l b )  that is 
combined with a P-subunit (GPIIIa  or P3) that is also found 
in  the vitronectin receptor (avP3) (2).  GPIIb-IIIa recognizes 
multiple ligands that include fibrinogen, fibronectin, von  Wil- 
lebrand  factor,  vitronectin, and possibly thrombospondin (3- 
6). While GPIIb-IIIa is present on the surface of resting and 
activated  platelets, it binds fibrinogen and mediates platelet 
aggregation only after  platelets  are activated (7). Once fibrin- 
ogen binds, GPIIb-IIIa  can  interact with the cytoskeleton (8), 
cluster on the platelet surface (9), permit phosphorylation of 
other  platelet  proteins  (10) and stimulate Na’/H’ exchange 
(11). In  addition,  GPIIb-IIIa may contribute to  the adherence 
of platelets to  the subendothelium (12). 
Despite the many functions associated with GPIIb-IIIa, 
little is known about mechanisms that regulate these func- 
tions. Phosphorylation is one possible regulatory mechanism, 
since multiple protein kinases are activated in agonist-stim- 
ulated  platelets (13-15). Although phosphorylation of several 
members of the integrin family, including the subunit of 
the CSAT antigen (16), a& (17), ~ V P S  (18),  and a& (19) has 
been reported, the relationship between phosphorylation and 
integrin function is currently unknown. 
We previously reported that  GPIIIa is phosphorylated pri- 
marily on threonine and  that  this phosphorylation increases 
2-4-fold in thrombin- or phorbol 12-myristate, 13-acetate 
(PMA)-activated  platelets  (20). The agonist-induced increase 
in 32Pi ncorporation was inhibited by prostacyclin, an inhib- 
itor of platelet  activation,  and  staurosporin, an inhibitor of 
protein kinase C (PKC). PKC is a phospholipid-dependent 
serine/threonine kinase that is abundant in platelets, directly 
activated by PMA, and indirectly activated by agonists that 
activate inositol lipid-dependent signaling (13,21).  These  data 
suggested that  GPIIIa phosphorylation could  be  involved in 
regulating an activation-dependent function of GPIIb-IIIa 
and  that  PKC may contribute to  this phosphorylation. 
The purpose of the present  study was 2-fold  first, to inves- 
tigate the functional significance of GPIIIa phosphorylation 
by determining the stoichiometry of this modification in 
intact  platelets,  and second, to evaluate the role of kinases in 
The abbreviations used are: GPIIb-IIIa, the glycoprotein IIh-IIIa 
complex; GPIIb, glycoprotein IIb; GPIIIa, glycoprotein IIIa; PtdOH, 
phosphatidic acid; PKC, protein kinase C; CaM kinase 11, Ca2+/ 
calmodulin dependent kinase 11; MLC, myosin light chain; mAb, 
monoclonal antibody; PMA, phorbol 12-myristate, 13-acetate; PG12, 
prostacyclin; BSA, bovine serum albumin; TLC, thin layer chroma- 
tography; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel 
electrophoresis; EGTA, [ethylenebis(oxyethylenenitrilo)]tetraacetic 
acid; HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid. 
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GPIIIa phosphorylation through in uitro studies. In  platelets, 
stoichiometric measurements based on the specific activity of 
[y3'P]ATP are complicated by large amounts of nonmeta- 
bolic ATP sequestered in dense granules (22). Therefore, we 
estimated the specific activity of [y3'P]ATP indirectly by 
employing an approach based on the work of Wilson et al. 
(23) and Holmsen et al. (24), who demonstrated that the 
specific activity of newly synthesized phosphatidic acid 
(PtdOH) equals the specific activity of the metabolic pool of 
[y"P]ATP in thrombin-stimulated  platelets. Using this 
method, the stoichiometry of GPIIIa phosphorylation was 
determined in resting and activated platelets and in the 
presence or absence of fibrinogen binding. GPIIIa phosphoryl- 
ation was further characterized by examining the character- 
istics of phosphorylation of purified GPIIb-IIIa by purified 
human  platelet  PKC  and purified Ca2+/calmodulin-dependent 
kinase I1 (CaM kinase 11). 
EXPERIMENTAL PROCEDURES 
Materials-Prostacyclin (PGI,), chloramine T, phenylmethylsul- 
fonyl fluoride, hirudin, PMA, protein A-Sepharose, phosphoserine, 
phosphothreonine, and phosphotyrosine were purchased from Sigma. 
:"Pi, carrier free, was obtained from ICN Biomedicals, Inc, Irvine, 
CA, "'1 was from Amersham Corp., and [-y3'P]ATP was from Du 
Pont-New England Nuclear. Bovine serum albumin (BSA) was ob- 
tained from Miles Laboratory. U46619  was purchased from Cayman 
Chemical Company, Ann Arbor, MI. Leupeptin was obtained from 
Vega Biotechnologies, Inc, Tucson, AZ, and DNase I from Boehringer 
Mannheim. Affi-Gel active ester agarose was obtained from Bio-Rad. 
Silica Gel G plates (10 X 10 cm) were obtained from Whatman, Kent, 
United Kingdom, and Chromagram cellulose thin layer chromatog- 
raphy (TLC) plates from Kodak. Bovine brain phosphatidyl serine 
and bovine brain diolein were from Avanti, Alabaster, AL. Ampho- 
lines were obtained from Pharmacia  LKB Biotechnology Inc. AP-3 
was generously supplied by Peter Newman, The Blood Center of 
Southeastern WI, Milwaukee, WI. Human  platelet PKC was gener- 
ously provided by Yusuf Hannun, Duke University, Durham, NC, 
and rat  brain CaM kinase I1 was kindly supplied by Howard Schul- 
man, Stanford University. Polyclonal anti-human platelet myosin 
antibodies and purified turkey gizzard  myosin  were gifts from James 
Sellers, National Institutes of Health. Mononclonal antibody (mAb) 
10E5 was supplied by Barry Coller, State University of New York, 
Stony Brook, NY, and mAb  LM142  was provided by David Cheresh, 
Scripps Clinic and Research Foundation, La Jolla, CA. Thrombin 
was supplied by John Fenton 11, New York State Department of 
Health, Albany,  NY. 
Preparation of Labeled Platelets-Freshly isolated platelets were 
obtained from healthy aspirin-free  adults as previously described (25) 
except that PGI, (50 ng/ml) was included throughout the washing 
procedure. Washed platelets were resuspended in buffer A (12 mM 
NaHCOa, 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 50 mM HEPES, 
pH 7.35) without PGI, at 1 X lo9 platelets/ml. The platelet suspension 
was incubated with "Pi (0.5 mCi/ml) at 37 "C for the specified times. 
The platelets were gently sedimented by centrifugation (730 X g, 15 
min) and resuspended in buffer A. 
Assays of Platelet Function-The functional status of washed, 32P- 
labeled platelets was determined by measuring fibrinogen binding to 
platelets and platelet aggregation. Fibrinogen was purified from hu- 
man plasma as previously described (26) and labeled with lZ5I by 
chloramine T (27). Fibrinogen binding experiments were performed 
as described (28), using washed platelets that were incubated at 37  'C 
for 4  h in buffer A but in the absence of 32P to simulate 32P-labeling 
conditions. Sedimented platelets were resuspended (0.5 to 2 x lo8/ 
ml) in buffer A with 2 mM CaCl,, 1 mM MgC12, and 0.5% BSA) and 
incubated for 30 min at room temperature with '2'II-labeled fibrinogen 
(0.2 to 2.5 pM), and either U46619 (0.5 p M )  or control buffer. To 
determine nonspecific binding, either 10-fold excess unlabeled fibrin- 
ogen or 100 nM  of mAb 10E5 was added to inhibit fibrinogen binding. 
Samples (50 pl) were layered onto a sucrose cushion (400 pl of 20% 
sucrose, 1% BSA, 2 mM CaCl, in buffer A) in 1.5-ml Eppendorf tubes 
followed by centrifugation (12,000 X g, 2 rnin). The radioactivity 
associated with the platelet pellet was quantitated by a Packard 
Cobra gamma counter. Specific binding was calculated by subtracting 
nonspecific binding from total binding. Platelet function was also 
determined by comparing the aggregation of freshly washed platelets 
to  that of platelets labeled with 32Pi for 4 h. Platelets (3 X 108/ml) in 
buffer A with 2 mM CaCl,, and 1 mM MgC1, were incubated with 200 
pg/ml fibrinogen at 37 "C under stirring conditions (Chronolog, Lumi 
Aggregometer) in the presence of agonist. 
Immunoprecipitation-Aliquots of 32P-labeled platelets (2.5 X 10' 
platelets in 0.5 ml) were incubated with 0.1 unit/ml  thrombin,  5 p~ 
PMA, 0.5 p M  U46619, or  appropriate control buffer for 0-5 min at 
37 "C without stirring.  In some experiments fibrinogen (200 pg/ml) 
and CaCl, (1 mM) or EDTA (5 mM)  were added to permit or inhibit 
fibrinogen binding. The reaction was terminated by adding an equal 
volume of ice-cold lysis buffer (2% Triton X-100, 20 mM Tris,  2 mM 
sodium metavanadate, 40 mM molybdic acid, 80 mM sodium pyro- 
phosphate, 40 mM KH2P04, 4 mM EGTA, 0.2 mM trifluoperazine, 0.2 
mM leupeptin, 2 mM phenylmethysulfonyl fluoride, 0.2 unit/ml hi- 
rudin, pH 7.1). After the removal of insoluble proteins by centrifu- 
gation (12,000 X g, 10 min), the  supernatant was incubated with 50 
pl of glycine-Affi-Gel beads (glycine was coupled at 5 mg/ml of Affi- 
Gel according to manufacturer's instructions) for 1 h at 4 "C to remove 
nonspecific binding proteins. The  supernatant was then incubated 
with 50 pl of AP-3-Affi-Gel beads (AP-3 is a specific anti-GPIIIa 
monoclonal antibody (29) which  was coupled at 1 mg/ml of Affi-Gel) 
for 3-18 h at 4 "C; control experiments revealed no difference in 
recovery of 32P-GPIIIa following these incubation times. To recover 
GPIIIa, AP-3-Affi-Gel beads were washed twice with 1.25 ml  of buffer 
B (150 mM NaCl, 0.1% Triton X-100, 0.02% NaN3, 20 mM Tris,  pH 
7.4) and GPIIIa was eluted in 200 11 of pH 12.5 elution buffer (0.1% 
Triton X-100,O.l M glycine) which  was subsequently neutralized with 
HCl. For immunoprecipitation of the vitronectin receptor, LM142, a 
mAb against av, (30) was coupled to Affi-Gel beads and incubated 
with platelet lysates as above. The samples were resolved by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 
7.5% polyacrylamide gel run  under reducing conditions by the method 
of Laemmli (31) as described (20). To determine the mass of GPIIIa, 
Coomassie-stained gels were scanned with a GS 300 densitometer 
(Hoefer Scientific Instruments) and compared to a simultaneously 
determined standard curve of GPIIIa of a known concentration. To 
quantitate  the radioactivity associated with GPIIIa, excised GPIIIa 
bands were dissolved with 0.5 ml  of hydrogen peroxide at 110 "C for 
1 h and  the radioactivity measured by liquid scintillation counting. 
Myosin Light Chain (MLC) Phosphorylation-As a positive control, 
MLC phosphorylation was determined using 32Pi-labeled platelets 
that were treated with 5 p~ PMA for 15 min at 37 "C and lysed as 
described above. Cytoskeletal proteins were sedimented by centrifu- 
gation (12,000 X g, 10 min), and  the myosin was separated by two 
methods. First, the entire cytoskeletal pellet was solubilized and 
subjected to 5-20% gradient SDS-PAGE under reducing conditions 
to resolve the myosin heavy chain and light chain. Second, myosin 
was immunoprecipitated following platelet lysis with a modified lysis 
buffer (lysis buffer with 2 mg/ml DNase I, 2 mg/ml leupeptin, and 
no EGTA) to enhance the solubilization of cytoskeletal proteins. 
After the removal of insoluble proteins by centrifugation (12,000 X g, 
10 min), the lysate was incubated with polyclonal anti-human platelet 
myosin antibodies at a 1:30 dilution, and  the myosin-antibody com- 
plex  was precipitated with protein A-Sepharose. Following washing 
with fresh lysis buffer, the protein A-Sepharose complex  was solubi- 
lized in Laemmli sample buffer and subjected to 5-20% gradient SDS- 
PAGE under reducing conditions. For both methods, the mass of 
myosin was determined by comparing the densitometric scan of 
platelet myosin  heavy chain in Coomassie-stained wet  gels to  that of 
a standard curve of purified myosin. The MLC band was cut  out  after 
autoradiography of dried gels, rehydrated in 0.5 ml  of water, dissolved 
in 0.5 ml of hydrogen peroxide for 1 h at 110 "C, and  the radioactivity 
measured by liquid scintillation counting. 
Isolation of Ph~spholipids-~~P-Labeled platelets (1 X 109/ml) in 
buffer A were incubated with thrombin (0.2 unit/ml) or control  buffer 
for 0-5 min at 37 "C. The reaction was stopped by adding 3.75 volumes 
of chloroform/methanol/HCl (200:400:5, v/v/v) and the phospho- 
lipids were extracted as described (32). The phospholipid extract was 
dried under a  stream of  N, and dissolved in 20-40 pl of chloroform. 
For isolation of polyphosphoinositides, the concentrated extract 
was chromatographed at  room temperature on 10 X 10-cm Silica Gel 
G  plates by two-dimensional TLC  as described by Ferrell and Huestis 
(33) with the first dimension in chloroform/methanol/NH40H 
(60:30:6, v/v/v) followed by chloroform/methanol/acetic acid 
(60:10:6, v/v/v). Radiolabeled phospholipids were detected by auto- 
radiography, and the polyphosphoinositides were excised with the 
radiation quantitated by liquid scintillation counting. 
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A two-step isolation was used for large scale PtdOH isolation (>1 
X IO9 platelets). The extract was applied across a silica-coated TLC 
plate 1 cm from the bottom and was chromatographed at room 
temperature initially in the first dimension only, separating the 
PtdOH from the majority of excess lipids. The location of radioactive 
PtdOH was determined by autoradiography, and  the area was excised 
and extracted twice. The concentrated extract was separated by two- 
dimensional TLC as described above. The location of PtdOH was 
again visualized by autoradiography, excised, extracted twice, and 
dried under a  stream of nitrogen. After wet digestion in perchloric 
acid, the mass of phosphate associated with PtdOH was determined 
with malachite green by the method of Itaya and Ui (34). Radioactiv- 
ity associated with PtdOH was determined by liquid scintillation 
counting. 
Stoichiometry Calculatiorw"he specific activity of  newly formed 
phosphatidic acid (dpm/pmol phosphate) was determined by the 
following formula: 
radioactivity of PtdOH (stimulated) 
- radioactivity of PtdOH (control) 
mass PtdOH (stimulated) - mass PtdOH (control) 
The stoichiometry of a phosphorylated protein (mole of phosphate/ 
mole  of protein)  in the same platelet sample was determined as: 
specific activity of platelet  protein (dpm/pmol protein) 
specific activity of PtdOH (dpm/pmol phosphate) 
Phosphorylation of Purified GPIIIa by Human Platelet PKC-Two 
to 7 pmol of purified GPIIb-IIIa (35) were incubated in a 100-pl 
solution containing 20 mM Tris,  pH 7.2, 5 mM MgC12, 0.2 mM CaC12, 
0.4  mg/ml phosphatidylserine, 0.02  mg/ml diolein, and 10 p M  [y"P] 
ATP (22,000 dpm/pmol) with 4 X units of purified platelet PKC 
(one unit of protein kinase activity is defined as the amount of 
enzyme needed to incorporate 1 pmol of phosphate  in  histone H1/ 
min). Initial phosphorylation studies were conducted in mixed mi- 
celles, with equal molar concentrations of Triton X-100 and phos- 
phatidylserine. To examine whether the presence of detergent af- 
fected phosphorylation, GPIIb-IIIa was reconstituted by detergent 
dialysis in phospholipid vesicles (69% phosphatidylserine, 30% phos- 
phatidylcholine, 1% diolein), as previously described (26). GPIIb-IIIa 
in vesicles was incubated with PKC  in the buffer described above. 
No additional lipids were added to activate the enzyme. Phosphoryl- 
ation reactions were carried out  at 30 "C for 60 min. Reactions were 
stopped by the addition of SDS Laemmli sample buffer. The samples 
were  resolved by SDS-PAGE followed  by autoradiography of dried 
gels. Following autoradiography, gels were rehydrated and  the 32Pi 
was quantitated by liquid scintillation counting. 
Phosphorylation of GPIIIa by CaM Kinuse II-Purified GPIIb-IIIa 
(2 pg)  was incubated at  30  "C for 10 min in  a total volume of 100  pl 
containing 1 pg  of CaM kinase 11, 20 mM Tris,  pH 7.4, either  3 mM 
CaC12 or 2 mM EGTA, 10 mM MgC12, 0.5 pg of calmodulin, and 20 
p M  [?"'PI ATP (22,000 dpm/pmol). The reaction was terminated by 
the addition of SDS sample buffer. 
Phosphoamino Acid  Analysis-The "P-labeled GPIIIa was excised 
from SDS-polyacrylamide gels and homogenized in 1 ml of 0.5 M 
ammonium bicarbonate, 0.1% SDS, and 1% @-mercaptoethanol. The 
homogenate was centrifuged, and  the protein  in the  supernatant was 
precipitated by the addition of trichloroacetic acid (15% final concen- 
tration) with 30 pg of BSA added as a carrier. The trichloroacetic 
acid-insoluble material was washed once with ethanol/ether (1:l) and 
incubated in 5.7 M HCl for 1 h at 110  "C. The sample was lyophilized 
to remove the HC1 and dissolved in 10 pl of H20 containing 1 mg/ml 
each of unlabeled phosphoserine, phosphothreonine, and phosphoty- 
rosine. The sample was spotted onto cellulose TLC plates and sepa- 
rated by electrophoresis and chromatography, as described by Cooper 
et al. (36). In brief, the samples were separated by electrophoresis a t  
500 V for 75 min in 88% formic acid/acetic acid/H,O, pH 1.9 
(50:156:1794, v/v/v). The plates were dried at room temperature and 
chromatographed (isobutyric acid, 0.5 M ammonium hydroxide, 5:3 
v/v). Following autoradiography, the 32P-labeled samples were iden- 
tified by their comigration with standards stained with ninhydrin. 
RESULTS AND DISCUSSION 
One purpose of this study was to investigate the functional 
significance of GPIIIa phosphorylation by measuring the stoi- 
chiometry of this modification. First, steady-state labeling 
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FIG. 1. Time course of 32Pi uptake into platelets and incor- 
poration into polyphosphoinositides and GPIIIa. At time 0, 32Pi 
(0.5 mCi/ml) was added to washed platelets (1 X 109/ml) at 37 'C. At 
the times indicated, 5 pl of platelets were sedimented (12,000 X g for 
2 min)  through 400 p1 of 20% sucrose and  the radioactivity associated 
with the platelet pellet was quantitated by Cerenkov counting (A); 
B ,  phospholipids were extracted from 20 pl of platelets and polyphos- 
phoinositides were isolated from the phospholipids by two-dimen- 
sional TLC  and  the radioactivity quantitated by liquid scintillation 
counting; C, GPIIIa was immunoprecipitated from 250 pl of platelet 
lysate with AP-3 antibody, resolved by 7.5% SDS-PAGE, and the 
associated radioactivity quantitated by liquid scintillation counting 
of solubilized gel bands. The graphs  represent the average (+S.D.) of 
four separate experiments, performed in  triplicate ( A )  or two separate 
experiments, performed in duplicate ( B  and C). 
conditions were identified for the uptake of 32Pi into  platelets 
and incorporation  into  substrates of interest. The time courses 
of 32Pi uptake into whole platelets and incorporation into 
polyphosphoinositides and  GPIIIa indicated that steady-state 
was approached within 4 h of labeling at 37 "C (Fig. 1); these 
labeling conditions were therefore used in all subsequent 
experiments. The function of platelets labeled under these 
conditions was assessed by measuring the ability of 32P- 
labeled platelets to aggregate and  bind fibrinogen. Aggregation 
in response to thrombin (0.1 unit/ml), U46619 (0.5 pM),  and 
PMA (5 PM) was identical for 32P-labeled platelets  and freshly 
washed control  platelets (U46619-induced aggregation is 
shown in Fig. 2). Platelets incubated under the above labeling 
conditions, except for the absence of 32Pi, specifically bound 
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FIG. 2. Aggregation of freshly  washed and 32P-labeled 
platelets. The ability of washed platelets to aggregate after being 
labeled for 4  h with :'jPi (0.5 mCi/ml) was compared to  that of freshly 
washed platelets as described under  "Experimental Procedures." 
TABLE I 
Stoichiometry of GPIIIa phosphorylation in whole platelets 
'"P-Labeled platelets (2.5 X 10' platelets  in 0.5 ml of buffer) were 
incubated at 37 "C with thrombin (0.1 unit/ml, 3  min, n = lo), U46619 
(0.5 pM, 5 min, n = l l ) ,  PMA (5 pM, 5 min, n = 7), or appropriate 
control buffer (3-5 min, n = 17). In some samples, fibrinogen (200 
pg/ml) and either CaC12 (2 mM) or EDTA (5 mM) were added to 
promote or inhibit fibrinogen binding. GPIIIa  or MLC were isolated 
by immunoprecipitation and  the stoichiometry of phosphorylation 
(mol of P/mol of protein) were determined as described under "Ex- 
perimental Procedures." The results shown are  the average (+ S.D.) 
of three  separate  experiments for GPIIIa  and two separate experi- 
ments for mvosin light chain. 
Protein  and  conditions  mol  P/ protein 
GPIIIa 
Resting platelets 0.012 (+0.004) 
Thrombin  stimulated 0.030 (fO.009) 
U46619 stimulated 
- Fibrinogen, Cap+,  EDTA 0.030 (f0.004) + Fibrinogen, Ca2+ 0.023 (k0.004) + Fibrinogen, EDTA 0.023 (f0.003) 
- Fibrinogen, Ca", EDTA 0.044 (f0.011) + Fibrinogen, Cap+ 0.031 (f0.005) + Fibrinogen, EDTA 0.034 (+0.001) 
PMA stimulated 
Myosin Light Chain 
PMA stimulated 1.23 (k0.16) 
Reported value (37) 1.20 
43,000 molecules of '2sI-fibrinogen/platelet when activated 
with U46619 (0.5 p ~ )  as compared to 1,600  molecules of "'1- 
fibrinogen/platelet in the resting state (average of triplicates 
from five separate experiments). This value is similar to 
previously reported values  for normal unlabeled platelets as 
measured  with similar concentrations of fibrinogen and plate- 
lets (28). Therefore, the function of platelets labeled by this 
method was normal as judged by aggregation and fibrinogen 
binding in response to agonists. 
To determine the stoichiometry of GPIIIa phosphorylation 
in platelets, the specific activity of the metabolic pool of 
[y:"P]ATP was  measured.  Because of the large pools of non- 
metabolic ATP sequestered in platelet dense granules, this 
specific activity was estimated indirectly by measuring the 
specific activity of newly synthesized PtdOH in thrombin- 
activated platelets. The specific activity of newly synthesized 
1 2 3 4 5 
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LM142 AP-3 
FIG. 3. Demonstration that the &-subunit of  the  vitronectin 
receptor is not responsible for the phosphorylation of GPIIIa 
observed in platelets. ?jP-Labeled platelets were treated with 
U46619 (0.5 p ~ )  or control buffer, and lysed. The vitronectin receptor 
was immunoprecipitated with LM142 (lanes 2 and 3 )  followed by the 
immunoprecipitation of GPIIIa with AP-3 (lanes 4 and 5 ) .  The "P- 
labeled samples were visualized by autoradiography of 7.5% SDS- 
polyacrylamide gels. Lanes 2 and 4, resting  platelets; lanes 3 and 5, 
U46619 treated platelets; lane 1, "sI-labeled GPIIb-IIIa standard.  The 
positions of GPIIb and GPIIIa are indicated. Note the absence of 
radioactivity in the  GPIIIa position in the lanes where LM142 (LYV 
antibody) was used. 
PtdOH was approximately 700 dpm/pmol phosphate in three 
separate experiments. To validate this method of determining 
the stoichiometry of phosphorylation of platelet proteins, 
MLC served as a positive control. MLC has been reported to 
be phosphorylated to a stoichiometry of  1.2  mol  of P/mol of 
MLC  when intact  platelets  are stimulated by PMA for 15 min 
as determined by a two-dimensional gel electropho- 
resis system that separates the differentially phosphorylated 
isoforms (37). When the stoichiometry of phosphorylation of 
MLC  was determined using the specific activity of PtdOH as 
an estimate of the specific activity of [y3*P]ATP, identical 
results were obtained (Table  I).  Thus, our results demonstrate 
that  this method is an effective approach for determining the 
stoichiometry of platelet protein phosphorylation. 
The stoichiometry of GPIIIa phosphorylation was deter- 
mined in resting and agonist-activated platelets. In unstimu- 
lated platelets, GPIIIa was phosphorylated to a level of  0.01 
mol of P/mol of GPIIIa  (Table  I). Maximal incorporation of 
32Pi into GPIIIa has been reported to occur at  3 min in 
thrombin-activated and 5 min in PMA-activated platelets 
(20). Platelets activated with the thromboxane A:! analog 
U46619 also maximally incorporated into GPIIIa at 5 min 
(data  not shown). In  platelets activated with thrombin, 
U46619, or PMA for times of maximal 32Pi incorporation, the 
amount of phosphorylated GPIIIa increased to approximately 
0.03 mol  of P/mol of GPIIIa  (Table  I).  This 3-fold increase is 
similar to previous observations (20). 
To determine if ligand binding affected the phosphorylation 
state of GPIIIa, the above experiments were repeated under 
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FIG. 4. Phosphorylation of purified GPIIb-IIIa by human 
platelet PKC. Purified GPIIb-IIIa was incubated  in  a total volume 
of 100 pl that contained 10 pl of purified platelet PKC (4 X pmol 
units) and [y-"2P]ATP as described under "Experimental Proce- 
dures." The reaction was stopped by the addition of SDS sample 
buffer. The samples were resolved by 7.5% SDS-PAGE  and visualized 
by autoradiography. Lane 1 contains  PKC  and GPIIb-IIIa; lane 2, 
PKC alone; and lane 3, GPIIb-IIIa alone. The multiple unmarked 
bands  are autophosphorylated PKC  and  PKC degradation  products, 
as well as trace contaminants phosphorylated by PKC. 
conditions that either permitted (+ fibrinogen, Ca2+) or in- 
hibited (+ fibrinogen, EDTA) fibrinogen binding (Table  I). 
The stoichiometry was not significantly different in either the 
presence or absence of fibrinogen binding, suggesting that 
ligand occupancy does not affect GPIIIa phosphorylation. 
Thus,  the stoichiometry of GPIIIa phosphorylation is low in 
resting platelets (0.01  mol of P/mol of GPIIIa), increases to 
approximately 0.03 mol of P/mol of GPIIIa in activated 
platelets  and appears unaffected by fibrinogen binding. 
The vitronectin receptor (a&), which contains the same 
P-subunit as GPIIb-IIIa, is also present on the surface of 
platelets, with approximately 100 copies/platelet (38). While 
Lam et al. (39) have reported that  the  anti-GPIIIa monoclonal 
antibody AP-3 does not immunoprecipitate detectable 
amounts of a& from platelets, it is possible that small 
amounts of highly phosphorylated a& may  be coprecipitat- 
ing with GPIIb-IIIa under the conditions used in this study. 
To determine whether or  not  the low levels of GPIIIa phos- 
phorylation were due to  the smaller population of a& becom- 
ing highly phosphorylated, avp3 was immunoprecipitated from 
'"P-labeled platelet lysate with LM142, a mAb against av (30), 
followed  by immunoprecipitation of GPIIIa (Fig. 3). No phos- 
phorylation of a& was observed. In contrast, the GPIIIa 
subsequently immunoprecipitated with AP-3 was phosphoryl- 
ated  to expected  levels. As a positive control, we found that 
LM142  did immunoprecipitate a& from '2sI-surface-labeled 
platelets (data not shown). Thus,  the low levels of GPIIIa 
phosphorylation cannot be explained by  low amounts of the 
a& becoming  highly phosphorylated. 
GPIIIa-, 
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FIG. 5. Phosphorylation of purified GPIIb-IIIa by CaM ki- 
nase 11. Purified GPIIb-IIIa  and CaM kinase I1 were incubated at  
30 "C for 10 min in a total volume of 100 pl that contained CaM 
kinase I1 and  [yR2P]ATP  as described under "Experimental Proce- 
dures." Samples were resolved by 7.5% SDS-PAGE and visualized by 
autoradiography. Lane 1 contains GPIIb-IIIa and CaM kinase 11; lune 
2, GPIIb-IIIa  and CaM kinase I1 incubated without calmodulin; lune 
3, GPIIb-IIIa and CaM  kinase I1 incubated with EGTA instead of 
CaCl,; lune 4, GPIIb-IIIa alone; and lane 5, CaM kinase I1 alone. The 
positions of molecular weight markers  are indicated. The unmarked 
bands are autophosphorylated CaM kinase 11. 
The characteristics of GPIIIa phosphorylation were further 
evaluated by phosphorylating purified GPIIb-IIIa with puri- 
fied platelet PKC. The autoradiogram in Fig. 4 illustrates 
that purified GPIIIa in detergent solution can be phosphoryl- 
ated in  vitro by purified PKC, under the appropriate condi- 
tions. However, the maximum stoichiometry observed was 
low (0.05 mol of P/mol of GPIIIa). Removal of contaminating 
vitronectin receptor (a,&) by  LM142 antibody affinity chro- 
matography did not alter in  vitro phosphorylation of GPIIIa 
by PKC (data not shown). To determine if the observed 
phosphorylation was low due to  the presence of Triton X- 
100, the  GPIIb-IIIa complex  was incorporated by detergent 
dialysis into phospholipid vesicles. Phosphorylation of recon- 
stituted  GPIIIa yielded a slightly higher stoichiometry (0.08 
mol of P/mol of GPIIIa). This low level of phosphorylation 
could be due to GPIIIa being a poor substrate for PKC, a 
restricted access of PKC to acceptor sites on GPIIIa, or the 
existence of a subpopulation of GPIIIa that is  more  readily 
phosphorylated. 
GPIIIa in platelets has been previously reported to be 
phosphorylated predominantly on threonine, with minimal 
amounts of phosphoserine also detected (20,  40). Under the 
steady-state labeling conditions described above and with 
thrombin stimulation (0.1 unit/ml,  3  min),  GPIIIa was  also 
phosphorylated predominantly on threonine (Fig. 6A) .  How- 
ever, phosphoamino acid analysis of GPIIIa that was phos- 
phorylated in uitro by purified PKC indicated that phos- 
phorylation was predominantly on serine (Fig. 6B).  Thus,  the 
previous speculation that  PKC may directly phosphorylate 
GPIIIa in intact platelets (20) now appears less  likely.  How- 
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FIG. 6. Phosphoamino acid analysis of GPIIIa phosphoryl- 
ated in thrombin-stimulated platelets ( A )  or in vitro by PKC 
( B )  or CaM kinase I1 (C). The '"P-labeled GPIIIa was isolated and 
acid hydrolyzed. The samples were mixed with  unlabeled  phosphoa- 
mino acid standards,  spotted  onto cellulose TLC  plates,  and  separated 
by electrophoresis, pH 1.9, and chromatography. The positions of 
'"P-labeled phosphoamino  acids were visualized by autoradiography. 
The circles show the positions of internal phosphoserine (PS), phos- 
phothreonine (PT), and phosphotyrosine ( P Y )  standards detected 
by staining with ninhydrin. 
ever, PKC may be part of a cascade to  activate  an unidentified 
protein kinase. 
Activation of inositol lipid hydrolysis results in mobilization 
of intracellular calcium and activation of calcium-dependent 
enzymes, including Ca'+/calmodulin-dependent protein ki- 
nase (41). This implies a possible interaction between inositol 
lipid hydrolysis, which is known to  activate  PKC,  and CaM 
kinase I1 activity. Therefore, CaM kinase 11, a ubiquitous 
serine-threonine specific kinase, was tested for its ability to 
phosphorylate GPIIIa in uitro. Fig. 5 illustrates that CaM 
kinase I1 can also phosphorylate GPIIIa.  This phosphoryla- 
tion is dependent  on the presence of Ca2+ and calmodulin and 
occurs with a higher stoichiometry (>0.5 mol of P/mol of 
GPIIIa). Phosphoamino acid analysis of GPIIIa phosphoryl- 
ated by CaM kinase I1 revealed that  both  threonine  and  serine 
residues were phosphorylated (Fig. 6C) which is more similar 
to  the phosphorylation pattern observed in intact platelets 
(20). While CaM kinase I1 has not yet been specifically 
detected  inplatelets,  multiple serine/threonine-specific 
kinases with increased activity in  thrombin-stimulated  plate- 
lets have recently been identified (15). 
In summary, we have provided evidence that  estimating  the 
specific activity of metabolic ATP by measuring the specific 
activity of newly synthesized PtdOH is an effective approach 
for  determining the stoichiometry of phosphorylation of plate- 
let proteins. The low stoichiometry of GPIIIa phosphorylation 
in both  resting and activated platelets suggests that  this  event 
is unlikely to affect  functions involving large populations of 
GPIIb-IIIa, such as its conversion to a fibrinogen receptor. 
This  is  further emphasized by the  fact  that  platelets subjected 
to  the  same  experimental conditions  retained the ability to 
bind fibrinogen and aggregate, which involves the majority of 
GPIIb-IIIa, while no more than 2-4% of GPIIIa becomes 
phosphorylated. The lack of change in  GPIIIa phosphoryla- 
tion in the presence or absence of fibrinogen binding suggests 
that GPIIIa phosphorylation is unaffected by ligand occu- 
pancy. While GPIIIa is a substrate for both  PKC  and CaM 
kinase I1 i n  uitro, only  CaM  kinase I1 phosphorylates GPIIIa 
to significant levels and with  a  phosphoamino acid pattern 
similar to  that observed in intact platelets. Thus, it is less 
likely than previously suspected that  PKC directly  phospho- 
rylates GPIlIa  in  intact platelets. However, the  PKC pathway 
may indirectly  affect the phosphorylation state of GPIIIa. 
Our results suggest the possibility that a readily phosphoryl- 
ated subpopulation of GPIIb-IIIa may exist,  with  potentially 
distinct  structural  or functional  properties.  Several  subpopu- 
lations of GPIIb-IIIa have been reported. These subpopula- 
tions include the 10-15% of GPIIb-IIIa  that is associated with 
the cytoskeleton of resting platelet membranes, which also 
binds  directly to  actin in vitro (42), and  the fraction of GPIIIa 
that is covalently bound to palmitic acid (0.1-0.3 mol of 
palmitate/mol of GPIIIa) (43). Two  forms of GPIIb mRNA 
have been identified in human platelets (44) and approxi- 
mately 3% of GPIIb from human  platelets undergoes alter- 
native  proteolytic processing (45); structurally different  sub- 
populations of GPIIb could potentially  affect the properties 
of the associated GPIIIa. Also, locational  subpopulations of 
GPIIb-IIIa include the approximately 30% of total platelet 
GPIIb-IIIa  that is distributed between the  a-granules  and  the 
open  canalicular  system (9,46). In addition, the limited  phos- 
phorylation of purified GPIIIa by PKC observed in  the pres- 
ent  study may suggest the existence of a subpopulation of 
GPIIIa.  The relationship between these different  subpopula- 
tions of GPIIb-IIIa  and  the phosphorylation state of GPIIIa 
remains  to be determined. 
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